Innoforce, a biopharmaceutical innovation enabling platform, and dMed, a clinical CRO with a strong presence in China and the U.S., have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.   “Our partnership with Innoforce will provide a powerful avenue to help clinical-stage therapeutic development programs from small and medium companies and to accelerate the pace of clin...